Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2L11 | O43521 | 1/20 | 0.41 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.39 |
| ▸ | PTK2 | Q05397 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | CDK1 | P06493 | 1/20 | 0.38 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.37 |
| ▸ | KLK1 | P06870 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24793164 | 0.77 | L3MBTL1 (0.43) | TP53NPSR1TSHRMAPTPDE4B | |
| SCHEMBL4768989 | 0.74 | MAPK14 (0.58) | CDK1 | |
| SCHEMBL14280045 | 0.73 | FGFR1 (0.42) | PTK2MEN1KMT2A | |
| SCHEMBL13931838 | 0.69 | L3MBTL1 (0.63) | BCL2L11BCL2L1MCL1TP53MAPT | |
| SCHEMBL8401935 | 0.68 | BCL2L11 (0.48) | BCL2L11BCL2L1MCL1NPSR1CNR2 | |
| SCHEMBL4851662 | 0.68 | MAPT (0.38) | TP53MAPTMEN1KMT2A | |
| SCHEMBL14014073 | 0.68 | MAPK14 (0.56) | TSHRMEN1KMT2AUSP2 | |
| SCHEMBL14158799 | 0.68 | MAPT (0.40) | TP53MAPTPDE4BMEN1KMT2A | |
| SCHEMBL5107331 | 0.67 | MAPK14 (0.58) | — | |
| SCHEMBL5113908 | 0.67 | MAPK8 (0.53) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7449472-B2 | Methods of inhibiting p38 with substituted bicyclic pyrimidines | ROCHE PALO ALTO LLC (US) | 2008-11-11 | — | — | US | disclosed |
| US-7449472-B2 | Methods of inhibiting p38 with substituted bicyclic pyrimidines | ROCHE PALO ALTO LLC (US) | 2008-11-11 | — | — | US | disclosed |
| US-7449472-B2 | Methods of inhibiting p38 with substituted bicyclic pyrimidines | ROCHE PALO ALTO LLC (US) | 2008-11-11 | — | — | US | disclosed |
| US-7439247-B2 | Bicyclic pyridine and pyrimidine P38 kinase inhibitors | ROCHE PALO ALTOP LLC (US) | 2008-10-21 | — | — | US | disclosed |
| US-7439247-B2 | Bicyclic pyridine and pyrimidine P38 kinase inhibitors | ROCHE PALO ALTOP LLC (US) | 2008-10-21 | — | — | US | disclosed |
| US-7439247-B2 | Bicyclic pyridine and pyrimidine P38 kinase inhibitors | ROCHE PALO ALTOP LLC (US) | 2008-10-21 | — | — | US | disclosed |
| EP-1485390-B1 | BICYCLIC PYRIDINE AND PYRIMIDINE P38 KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2008-10-08 | — | — | EP | disclosed |
| EP-1485390-B1 | BICYCLIC PYRIDINE AND PYRIMIDINE P38 KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2008-10-08 | — | — | EP | disclosed |
| US-7091347-B2 | Bicyclic pyridine and pyrimidine p38 kinase inhibitors | ROCHE PALO ALTO LLC (US) | 2006-08-15 | — | — | US | disclosed |
| US-20060084803-A1 | Bicyclic pyridine and pyrimidine P38 kinase inhibitors | CHEN JIAN J | 2006-04-20 | — | — | US | disclosed |
| US-20050288312-A1 | Bicyclic pyridine and pyrimidine p38 kinase inhibitors | CHEN JIAN J | 2005-12-29 | — | — | US | disclosed |
| US-20030207900-A1 | Bicyclic pyridine and pyrimidine p38 kinase inhibitors | ROCHE PALO ALTO LLC | 2003-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288312-A1 | Bicyclic pyridine and pyrimidine p38 kinase inhibitors | MAPK1, MAP3K1, MAP3K8 | BCL2L11 2558/4885BCL2L1 2928/4885MCL1 1002/4885 |
| US-20030207900-A1 | Bicyclic pyridine and pyrimidine p38 kinase inhibitors | MAPK1, MAP3K1, MAPKAPK2 | BCL2L11 2470/4885BCL2L1 2713/4885MCL1 630/4885 |
| US-20060084803-A1 | Bicyclic pyridine and pyrimidine P38 kinase inhibitors | MAPK1, MAP3K1, MAP3K8 | BCL2L11 2558/4885BCL2L1 2928/4885MCL1 1002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.